WO2022025783A1 - Применения комбинации генов ангиогенных и нейротрофических факторов - Google Patents
Применения комбинации генов ангиогенных и нейротрофических факторов Download PDFInfo
- Publication number
- WO2022025783A1 WO2022025783A1 PCT/RU2020/000387 RU2020000387W WO2022025783A1 WO 2022025783 A1 WO2022025783 A1 WO 2022025783A1 RU 2020000387 W RU2020000387 W RU 2020000387W WO 2022025783 A1 WO2022025783 A1 WO 2022025783A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- skeletal muscle
- injury
- subject
- regeneration
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 30
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract description 10
- 102000007072 Nerve Growth Factors Human genes 0.000 title abstract description 8
- 239000003900 neurotrophic factor Substances 0.000 title abstract description 8
- 239000002870 angiogenesis inducing agent Substances 0.000 title description 5
- 230000002491 angiogenic effect Effects 0.000 title description 4
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 31
- 230000008929 regeneration Effects 0.000 claims abstract description 28
- 238000011069 regeneration method Methods 0.000 claims abstract description 28
- 210000004126 nerve fiber Anatomy 0.000 claims abstract description 19
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 18
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 13
- 208000014674 injury Diseases 0.000 claims abstract description 9
- 230000008736 traumatic injury Effects 0.000 claims abstract description 8
- 239000013613 expression plasmid Substances 0.000 claims abstract description 7
- 238000003259 recombinant expression Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 34
- 208000028867 ischemia Diseases 0.000 claims description 20
- 230000033115 angiogenesis Effects 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 210000003141 lower extremity Anatomy 0.000 claims description 13
- 206010009192 Circulatory collapse Diseases 0.000 claims description 11
- 206010040560 shock Diseases 0.000 claims description 11
- 210000003205 muscle Anatomy 0.000 claims description 10
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 102100022987 Angiogenin Human genes 0.000 claims description 7
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 7
- 101000757236 Homo sapiens Angiogenin Proteins 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 208000020431 spinal cord injury Diseases 0.000 claims description 7
- 208000029549 Muscle injury Diseases 0.000 claims description 6
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- 208000010392 Bone Fractures Diseases 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 3
- 206010028331 Muscle rupture Diseases 0.000 claims description 2
- 206010043248 Tendon rupture Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 12
- 230000026341 positive regulation of angiogenesis Effects 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000013130 cardiovascular surgery Methods 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000001023 pro-angiogenic effect Effects 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000013600 plasmid vector Substances 0.000 description 8
- 230000002638 denervation Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000013127 Vimentin Human genes 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000027746 artery morphogenesis Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000049982 HMGA2 Human genes 0.000 description 1
- 108700039143 HMGA2 Proteins 0.000 description 1
- 101150073387 Hmga2 gene Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Definitions
- the invention relates to genetic engineering, biotechnology and medicine, and specifically to the stimulation of angiogenesis, regeneration of nerve fibers of blood vessels and regeneration of skeletal muscle, and can be used to treat conditions associated with circulatory failure, in particular in cardiovascular surgery, as well as treatment neurodegenerative diseases and traumatic injuries of the skeletal muscle, using a combination of genes encoding the synthesis of proangiogenic and neurotrophic factors.
- ischemia in particular chronic ischemia of the lower extremities, is treated with medication and surgery, however, none of the methods used in practical medicine completely eliminates the underlying cause and does not lead to a complete restoration of the microcirculation of the affected tissue.
- ischemic damage consisting in a decrease in the proliferation index of endothelial cells, capillary density, an increase in the NGF secretion index, an increase in the VEGF secretion index, were more pronounced in the ischemia + denervation compared with the ischemia group, which indicates the role of nerve fibers in ischemia.
- the RF patent for the invention Ns 2517117 “Method for stimulating nerve regeneration using a nanostructured matrix and genetic constructs” is known, however, this invention relates to the regeneration of the nerve only, and is not related to the growth of blood vessels.
- composition and method for regulating vascular development [RU2365382], which involves administering an EGFL7-aHTaroHHCTa antagonist of vascular endothelial cell growth factor VEGF to an individual.
- this method is used to suppress angiogenesis rather than stimulate it.
- the objective of the present invention is to develop a new effective method for stimulating angiogenesis, regeneration of nerve fibers of blood vessels and/or regeneration of skeletal muscle, as well as to expand the arsenal of technical means in this field.
- the technical result consists in the development of a new effective and safe method for stimulating angiogenesis, regeneration of nerve fibers of blood vessels and/or regeneration of skeletal muscle, which is characterized by a more pronounced increase in angiogenesis and regenerative processes, and thus is characterized by high efficiency for the treatment of conditions and/or diseases associated with with circulatory failure, neurodegenerative diseases and/or traumatic injuries of the skeletal muscle, in addition, this method according to the invention is not accompanied by the occurrence of unwanted immune reactions.
- the present invention solves a complex problem - stimulation of angiogenesis through angiogenic factors (VEGF + ANG) with simultaneous regeneration of nerve fibers of blood vessels by neurotrophic factor (GDNF) and/or regeneration of skeletal muscle, as a result, the invention provides, in particular, the efficient creation of stable functional blood vessels.
- VEGF + ANG angiogenic factors
- GDNF neurotrophic factor
- the combination according to the invention based on plasmid constructs provides a complex effect on the key processes necessary for the regeneration of organs and tissues - it induces the formation of stable and functionally mature vessels, ensures the regeneration of the nerve fibers of blood vessels and the regeneration of skeletal muscle.
- the specified technical result is achieved by developing and obtaining a combination of a recombinant expression plasmid pBudK-coVEGF-coANG, including a nucleotide sequence encoding a VEGF protein, and a nucleotide sequence encoding an ANG protein, and a recombinant expression plasmid pBudK-coGDNF, including a nucleotide sequence encoding a GDNF protein; for induction of angiogenesis, regeneration of nerve fibers of blood vessels and/or regeneration of skeletal muscle.
- This plasmid combination allows simultaneous expression of several recombinant genes and exhibits high functional activity.
- the plasmid pBudK-coVEGF-coANG is characterized by the sequence SEQ ID NO: 1.
- the pBudK-coGDNF plasmid is characterized by the sequence SEQ ID NO:2.
- the present invention also includes the use of a combination of the invention for the prevention and/or treatment of a condition and/or disease associated with circulatory failure, neurodegenerative disease and/or traumatic skeletal muscle injury in a subject.
- the condition and/or disease associated with circulatory failure is coronary heart disease, ischemia of the lower extremities.
- the neurodegenerative disease is amyotrophic lateral sclerosis, peripheral nerve injury, spinal cord injury.
- a traumatic injury to the skeletal muscle is a rupture of a muscle or tendon, a fracture of a bone.
- the combination is administered to the subject intramuscularly.
- the present invention also includes a method for inducing angiogenesis, regenerating blood vessel nerve fibers and/or regenerating skeletal muscle in a subject, comprising administering to the subject a combination of the invention.
- the subject is characterized by the presence of a state and/or circulatory failure disease, neurodegenerative disease and/or traumatic skeletal muscle injury.
- the condition and/or disease associated with circulatory failure is coronary heart disease, ischemia of the lower extremities.
- the neurodegenerative disease is amyotrophic lateral sclerosis, peripheral nerve injury, spinal cord injury.
- a traumatic injury to a skeletal muscle is a rupture of a muscle, tendon, or a fracture of a bone.
- the combination is administered to the subject intramuscularly.
- the combination and method according to the invention are promising for use in medicine, namely for the stimulation of angiogenesis, more specifically for the treatment of conditions associated with circulatory failure, as well as the treatment of neurodegenerative diseases and traumatic injuries of the skeletal muscle, and can be used in cardiovascular surgery for treatment of conditions associated with insufficient blood circulation (in particular, coronary heart disease, ischemia of the lower extremities), with impaired neurotrophic function, for the treatment of neurological diseases (in particular, amyotrophic lateral sclerosis, peripheral nerve injury, spinal cord injury).
- insufficient blood circulation in particular, coronary heart disease, ischemia of the lower extremities
- neurological diseases in particular, amyotrophic lateral sclerosis, peripheral nerve injury, spinal cord injury.
- the subject of the present invention is also a method for the prevention and/or treatment of a condition and/or disease in a subject associated with insufficient blood circulation (in particular coronary heart disease, ischemia of the lower extremities), with impaired neurotrophic function, a method for the treatment of neurodegenerative diseases (in particular , amyotrophic lateral sclerosis, peripheral nerve injury, spinal cord injury).
- a condition and/or disease in a subject associated with insufficient blood circulation in particular coronary heart disease, ischemia of the lower extremities
- impaired neurotrophic function a method for the treatment of neurodegenerative diseases (in particular , amyotrophic lateral sclerosis, peripheral nerve injury, spinal cord injury).
- the present invention can be used, in particular for the treatment of coronary heart disease, diabetic angio- and neuropathy, in sports medicine.
- the new gene construct according to the invention it is possible to use this gene construct in sports medicine and traumatology in such conditions as: muscle and tendon ruptures, severe bone fractures.
- muscle and tendon ruptures severe bone fractures.
- severe bone fractures severe bone fractures.
- the present invention can be used both as a stand-alone therapy and in combination with surgery to enhance the effect of the operation.
- the obtained experimental data demonstrated a pronounced effect stimulating skeletal muscle regeneration, which can be effective in various traumatic muscle injuries (in athletes, injuries, etc.).
- the effect of enhancing angiogenesis may have a wide prospect of use, in particular, in sports medicine and traumatology.
- GDNF glial neurotrophic factor
- FIG. 1 Map of the plasmid vector pBudK-coGDNF (4183 bp).
- Figure 3 Comparison of the results of determination of connective tissue protein vimentin after ischemia in a sample using a combination of plasmids according to the invention and in a control sample.
- tissue refers to a system of cells and non-cellular structures that have a common structure, in some cases a common origin, and specialized in performing certain functions.
- induction of angiogenesis refers to the stimulation of the growth of new blood vessels.
- regeneration of nerve fibers of blood vessels refers to the regeneration of nerve tissues by repair damaged tissues (restoration of structure and function) and / or stimulation of the growth of nerve fibers.
- regeneration of skeletal muscle refers to the regeneration of muscle tissue by repairing damaged muscle fibers (restoration of structure and function) and/or stimulating the growth of new muscle fibers.
- Plasmids used as vectors are circular double DNA molecules separated from the bacterial or yeast chromosome, capable of copying independently of the microorganism's own chromosomes. Plasmids specially designed for molecular cloning are usually small (a few kilobases in size) and contain three essential components: an original for replication (copy in E. coli or in yeast), one or more selective markers (for example, a gene that determines antibiotic resistance) and one or more restriction sites that can be used to remove foreign DNA. Important steps involved in plasmid cloning of foreign DNA with the EcoRI restriction site. Identification of colonies that contain the desired recombinant plasmid, followed by mass growth and isolation of pure plasmid DNA, allows the accumulation of large amounts of cloned insert.
- the subject matter of this invention also includes administering to a subject in need of appropriate treatment a therapeutically effective amount of a combination of the invention.
- therapeutically effective amount means that amount of the combination of the invention which, when administered as mono- or combination therapy, causes induction of angiogenesis, regeneration of blood vessel nerve fibers and/or regeneration of skeletal muscle.
- therapeutically effective amount refers to the combination of amounts of active ingredients, the administration of which leads to a preventive or therapeutic effect when taken sequentially or simultaneously. The exact amount required may vary from subject to subject, depending on the species of the mammal, the age and general condition of the patient, the severity of the disease, the method of administration, combination treatment with other drugs, and the like.
- the combination of the invention may be administered to the patient in any amount and by any route of administration effective for treatment and/or prophylaxis, preferably intramuscularly.
- the amount of a combination of the invention that will be effective in the treatment or prevention of a particular disorder or condition depends, in particular, on well-known factors affecting effective dosage of drugs.
- the exact dosage level determined by the attending physician depends on well-known factors, including the route of administration, as well as the age, body weight, sex and general health of the patient; the nature, severity and clinical condition of the disease; use (or non-use) of concomitant therapy.
- the invention also relates to pharmaceutical compositions which contain the combination of the invention and one or more pharmaceutically acceptable carriers, diluents and/or excipients. These compositions may also contain one or more additional therapeutic agents.
- the combination of the present invention may be administered to a subject in need of appropriate therapy in combination with one or more other therapeutic regimens.
- compositions of the invention contain a combination of this invention together with pharmaceutically acceptable carriers, which may include any solvents, diluents, dispersions or suspensions, surfactants, isotonic agents, thickeners and emulsifiers, preservatives, astringents, lubricants, etc. suitable for a particular dosage form.
- pharmaceutically acceptable carriers may include any solvents, diluents, dispersions or suspensions, surfactants, isotonic agents, thickeners and emulsifiers, preservatives, astringents, lubricants, etc. suitable for a particular dosage form.
- the conventional carrier medium is not compatible with the plasmid combination of the invention, such as any undesirable biological effects or other undesirable interactions with any other component(s) of the pharmaceutical composition, the use of such compositions is within the scope of this invention.
- the compositions are a solution comprising a combination of the invention (1:1 ratio of plasmids) and sterile isotonic sodium chlor
- Plasmid vectors pBudK 1. Plasmid vectors pBudK
- the pBudK vector a vector designed for the simultaneous cloning of two genes.
- the vector contains the human cytomegalovirus immediate-early promoter (CMV) and the human elongation factor EF1 alpha (Human elongation factor 1a subunit) promoter for independent expression of two genes.
- CMV human cytomegalovirus immediate-early promoter
- EF1 alpha Human elongation factor 1a subunit
- Codon optimization increases the efficiency of mRNA translation into polypeptides, thereby increasing the efficiency of expression vectors used, among other things, in gene therapy.
- the most frequently occurring synonymous codons of the genes of the recipient organism are used as optimal codons. It is believed that such modifications can increase the efficiency of expression of the therapeutic gene. Optimization of the codon composition is implemented using site-directed mutagenesis or de novo chemical synthesis of the nucleotide sequence.
- the wild-type nucleotide sequences of the coding part of the VEGF, ANG, GDNF genes contain a tandem of rare codons that can stop translation or reduce its efficiency.
- the codon adaptation index CAI English Codon Adaptation Index
- the GC composition was optimized and extended regions with a high content of GC nap were removed.
- the optimization process removed potential cis-acting sites.
- the amino acid sequences of the VEGF, ANG, and GDNF genes did not change.
- the two-cassette plasmid vector pBudCE4.1 was modified:
- the sequence of the zeocin resistance gene and its promoter are replaced by the sequence of the kanamycin resistance gene.
- Zeocin and kanamycin resistance genes are used both for selection of the plasmid vector in bacterial cells and for selection of eukaryotic cells transfected with the plasmid vector.
- the replacement of the zeocin resistance gene is due to the fact that its expression in eukaryotic cells (including human cells) leads to the appearance of a foreign protein (gene expression product), which can cause the emergence of antibiotic resistance and be a potential allergen. As a result, the likelihood of unwanted immune reactions was reduced.
- Example 1 Evaluation of the induction of angiogenesis after the introduction of plasmids with angiogenic and neurotrophic factors.
- IHC immunohistochemical
- CD31 endothelial cell markers
- Laser Doppler flowmetry makes it possible to quantify perfusion in the ischemic limb after the introduction of genetic constructs. An increase in perfusion in the ischemic limb by 45% was found after the introduction of genetic constructs according to the invention.
- Example 2 Determination of connective tissue protein by Western blot after ischemia and introduction of plasmids with angiogenic and neurotrophic factors.
- Western blotting is a procedure involving the separation of a mixture of proteins by gel electrophoresis followed by electrotransfer to a suitable membrane (eg, PVDF). Once proteins have been transferred to a PVDF membrane, they can be stained for visualization and directly identified by N-terminal sequencing, mass spectrometry, or immunoassay. Immunodetection involves the identification of a protein through its reaction with a specific antibody. Due to the spatial resolution, this method provides information about the molecular mass of individual proteins and distinguishes between isoforms, intermediates, and other post-translationally modified forms.
- a suitable membrane eg, PVDF
- Antigen-antibody complexes were detected with Horseradish Conjugated Antibodies (HRP) and designed using the ECL Western Blot Substrate Kit (HRP) according to the manufacturer's instructions (Life Technologies, Carlsbad, CA, USA). Band density was quantified using Image J version 1.46 after background subtraction and normalized to b-actin level.
- HRP Horseradish Conjugated Antibodies
- Vimentin is a protein of intermediate filaments of connective tissues and other tissues of mesodermal origin.
- the decrease in vimentin in the groups in which the plasmid combination of the invention was used can be considered as a decrease in the amount of connective tissue (i.e., fibrosis) in the muscles, i.e. a decrease in the degree of ischemia compared with the control (table 2, fig.3).
- the present invention is promising for improving the treatment of connective tissue injuries and/or diseases of the human musculoskeletal system.
- this applies to traumatic injuries of the skeletal muscle.
- the results of the experiments showed that with the introduction of this genetic construct, the number of central nuclear muscle fibers increased by 81 times compared with the control group (the control group was injected with NaCl). An increase in the number of central nuclear muscle fibers occurs in the phase of active regeneration of the skeletal muscle, which is an unobvious evidence of the regenerative effect of the use of this gene construct.
- the combination of two double-cassette plasmids of the invention allows simultaneous expression of genes, which increases the effectiveness of the gene therapy carried out due to the presence of synergy between genes through the simultaneous expression of therapeutic genes of the invention.
- a higher biosafety of the plasmid vector one can count on a more pronounced increase in angiogenesis and an increase in regenerative processes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2020/000387 WO2022025783A1 (ru) | 2020-07-28 | 2020-07-28 | Применения комбинации генов ангиогенных и нейротрофических факторов |
DE212020000830.2U DE212020000830U1 (de) | 2020-07-28 | 2020-07-28 | Verwendung einer Kombination von Genen angiogener und neurotropher Faktoren |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2020/000387 WO2022025783A1 (ru) | 2020-07-28 | 2020-07-28 | Применения комбинации генов ангиогенных и нейротрофических факторов |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022025783A1 true WO2022025783A1 (ru) | 2022-02-03 |
Family
ID=80036626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2020/000387 WO2022025783A1 (ru) | 2020-07-28 | 2020-07-28 | Применения комбинации генов ангиогенных и нейротрофических факторов |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE212020000830U1 (ru) |
WO (1) | WO2022025783A1 (ru) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2459630C1 (ru) * | 2011-04-27 | 2012-08-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) | Способ стимулирования нейрогенерации с помощью генетических конструкций |
RU2665771C1 (ru) * | 2017-03-17 | 2018-09-04 | Общество с ограниченной ответственностью "Медсервис" | Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена ang и/или уменьшением количества и/или активности белка ангиогенина на основе генно-терапевтических субстанций с геном ang, способ получения и использования |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005249377A1 (en) | 2004-04-14 | 2005-12-15 | Genentech, Inc. | Compositions and methods comprising an EGFL7 antagonist for modulating vascular development |
US9022948B2 (en) | 2011-08-26 | 2015-05-05 | Symap Holding Limited | System and method for locating and identifying the functional nerves innervating the wall of arteries |
KR20140121317A (ko) | 2013-04-06 | 2014-10-15 | 서울대학교산학협력단 | 비신경 세포로부터 유도 신경 줄기 세포의 생산 방법 및 이에 의하여 생산되는 유도 신경 줄기 세포 |
-
2020
- 2020-07-28 WO PCT/RU2020/000387 patent/WO2022025783A1/ru active Application Filing
- 2020-07-28 DE DE212020000830.2U patent/DE212020000830U1/de active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2459630C1 (ru) * | 2011-04-27 | 2012-08-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) | Способ стимулирования нейрогенерации с помощью генетических конструкций |
RU2665771C1 (ru) * | 2017-03-17 | 2018-09-04 | Общество с ограниченной ответственностью "Медсервис" | Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена ang и/или уменьшением количества и/или активности белка ангиогенина на основе генно-терапевтических субстанций с геном ang, способ получения и использования |
Non-Patent Citations (3)
Title |
---|
DATABASE NUCLEOTIDE 28 July 2020 (2020-07-28), ANONYMOUS : "Pomacea nobilis isolate W10Pun cytochrome c oxidase subunit I (COI) gene, partial cds; mitochondrial", XP055904623, retrieved from NCBI Database accession no. MN325105 * |
KRAKORA DAN ET AL: "Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model.", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 21, no. 8, 1 August 2013 (2013-08-01), GB , pages 1602 - 1610, XP002774490, ISSN: 1525-0024, DOI: 10.1038/mt.2013.108 * |
PLOTNIKOV M.B. ET AL.: "Pervye rezultaty klinicheskogo primeneniia priamoi gennoi terapii VEGF i bFGF pri lechenii patsientov s khronicheskoi ishemiei nizhnikh konechnostei", PRAKTICHESKAIA MEDITSINA, vol. 2, 25 September 2013 (2013-09-25), pages 123 - 125, XP009534723, ISSN: 2072-1757 * |
Also Published As
Publication number | Publication date |
---|---|
DE212020000830U1 (de) | 2023-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7816321B2 (en) | Thymosin β4 derivatives and use thereof | |
US20160250290A1 (en) | Gene therapy for diabetic ischemic disease | |
TW200520772A (en) | Muteins of fibroblast growth factor 21 | |
RU2008136655A (ru) | Гибридные белки рецептора vegf, их фармацевтические композиции и терапевтическое применение при заболеваниях глаз | |
JP2021500029A (ja) | Nt−3遺伝子治療のための方法及び材料 | |
JP2017532021A (ja) | コドン最適化組み換えプラスミド、末梢神経再生の刺激方法、及び損傷ヒト神経の治療様式 | |
RU2486918C1 (ru) | Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций | |
JP2023520285A (ja) | 代謝障害に対する新規なfgf19タンパク質類似物質及びその使用 | |
RU2805082C2 (ru) | Способ стимулирования ангиогенеза, лечения нейродегенеративных заболеваний и регенерации скелетной мышцы с помощью плазмидных конструкций с генами ангиогенных и нейротрофических факторов | |
WO2022025783A1 (ru) | Применения комбинации генов ангиогенных и нейротрофических факторов | |
JP2016536306A (ja) | ヒト・リラキシン類似体、その医薬組成物及びその医薬用途 | |
JPWO2019140283A5 (ja) | アクチビンiib型受容体変異体および同変異体を含む医薬組成物 | |
US11510999B2 (en) | Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms | |
CN110577589B (zh) | 胰岛素样生长因子结合蛋白4突变体及其制药用途 | |
RU2737487C1 (ru) | Генно-инженерная конструкция для стимуляции ангиогенеза | |
US20220378841A1 (en) | Modified cells and related methods | |
US20220088139A1 (en) | Nerve growth factor mutant | |
RU2628706C2 (ru) | Способ стимуляции ангиогенеза в ишеминизированных тканях и комбинированное лекарственное средство для осуществления способа | |
EP1161441A1 (en) | Compositions for promoting nerve regeneration | |
Ji | Molecular determinants of excitability of hindlimb motoneurons after complete spinal cord transection and BDNF overexpression: PhD thesis | |
US6930094B1 (en) | Tissue factor for influencing blood vessel formation | |
WO2022049280A1 (en) | Peptides endowed with angiogenic activity | |
EP1556494A2 (en) | Bicistronic vector encoding a vegf and an fgf, use thereof | |
Rendell | SB-509 | |
WO2001093888A2 (en) | A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20947222 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 212020000830 Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20947222 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 29.06.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20947222 Country of ref document: EP Kind code of ref document: A1 |